[go: up one dir, main page]

CN105622501B - N-芳基-3-碘代喹啉衍生物及其制备方法 - Google Patents

N-芳基-3-碘代喹啉衍生物及其制备方法 Download PDF

Info

Publication number
CN105622501B
CN105622501B CN201610191732.2A CN201610191732A CN105622501B CN 105622501 B CN105622501 B CN 105622501B CN 201610191732 A CN201610191732 A CN 201610191732A CN 105622501 B CN105622501 B CN 105622501B
Authority
CN
China
Prior art keywords
propargyl alcohol
phenyl
substituted
preparation
diphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201610191732.2A
Other languages
English (en)
Other versions
CN105622501A (zh
Inventor
王少印
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wannan Medical College
Original Assignee
Wannan Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wannan Medical College filed Critical Wannan Medical College
Priority to CN201610191732.2A priority Critical patent/CN105622501B/zh
Publication of CN105622501A publication Critical patent/CN105622501A/zh
Application granted granted Critical
Publication of CN105622501B publication Critical patent/CN105622501B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本发明涉及N‑芳基‑3‑碘代喹啉衍生物及其制备方法,衍生物结构式为：或者

Description

N-芳基-3-碘代喹啉衍生物及其制备方法
技术领域
本发明涉及有机合成技术领域，具体涉及N-芳基-3-碘代喹啉衍生物及其制备方法。
背景技术
喹啉衍生物广泛存在于生物碱中，是一类重要的生物活性成分。喹啉的衍生物具有多样的药理作用，如有较强的抗疟疾(Larsen,R.D.；Corley,E.G.；King,A.O.；Carroll,J.D.；Davis,P.；Verhoeven,T.R.；Reider,P.J.；Labelle,M.；Gauthier,J.Y.；Xiang,Y.B.；Zamboni,R.J.,J.Org.Chem.1996,61,3398.)平喘(Dubé,D.；Blouin,M.；Brideau,C.；Chan,C.-C.；Desmarais,S.；Ethier,D.；Falgueyret,J.-P.；Friesen,R.W.；Girard,M.；Girard,Y.；Guay,J.；Riendeau,D.；Tagari,P.；Young,R.N.,Bioorg.Med.Chem.Lett.1998,8,1255.)，抗高血压(Ferrarini,P.L.；Mori,C.；Badawneh,M.；Calderone,V.；Greco,R.；Manera,C.；Martinelli,A.；Nieri,P.；Saccomanni,G.,Eur.J.Med.Chem.2000,35,815.)，抗细菌(Chen,Y.-L.；Fang,K.-C.；Sheu,J.-Y.；Hsu,S.-L.；Tzeng,C.-C.,J.Med.Chem.2001,44,2374.)，抗炎((a)Roma,G.；Di Braccio,M.；Grossi,G.；Mattioli,F.；Ghia,M.,Eur.J.Med.Chem.2000,35,1021-1035；(b)Kalluraya,B.；Sreenivasa,S.,IlFarmaco 1998,53,399.)等作用。因此，对喹啉类衍生物进行结构改造来开发喹啉衍生物药物是国内外的热点。喹啉的传统合成方法包括Skraup合成法，Combes合成法、Doebner-Miller合成法、合成法、Conrad-Limpach-Knorr合成法、Pfitzinger合成法以及陈超课题组最近发表的[2+2+2]喹啉合成法等((a)Marco-Contelles,J.；Pérez-Mayoral,E.；Samadi,A.；Carreiras,M.C.；Soriano,E.Chem.Rev.2009,109,2652.(b)Kouznetsov,V.V.；Mendez,L.Y.；Gomez,C.M.Curr.Org.Chem.2005,9,141.(c)Cheng,C.C.；Yan,S.J.Org.React.1982,28,37.(d)Reitsema,R.H.Chem.Rev.1948,43,43.(e)Bergstrom,F.W.Chem.Rev.1944,35,77.(f)Wang,Y.；Chen,C.；Peng,J.；Li,M.Angew.Chem.Int.Ed.2013,52,5323.)
发明内容
本发明的目的是提供N-芳基-3-碘代喹啉衍生物及其制备方法。
本发明采用的技术方案是：
N-芳基-3-碘代喹啉衍生物，其结构式为：
或者
式中，R1～R4为H、C1～C4直链或支链烃基、C1～C4直链或支链烷氧基；R5为苯基或取代苯基、C1～C4直链或支链烃基；R6、R7为苯基或取代苯基；
所述R5、R6、R7为取代苯基时，取代苯基上的取代基为C1～C4直链或支链烃基、C1～C4直链或支链烷氧基或卤素；所述的C1～C4直链烃基为甲基、乙基、丙基或丁基，支链烃基为异丙基、异丁基；
R1、R2、R3和R4可以相同或不同，R6和R7可以相同或不同；
优选的R1、R4为H，R2、R3为甲氧基。
一种N-芳基-3-碘代喹啉衍生物的制备方法，步骤包括：
A、将取代的芳香基叠氮、取代的炔丙醇与碘在有机溶剂中加热回流，反应12小时以上；
B、减压除去溶剂得到粗产物，将粗产物分离提纯得到产物即N-芳基-3-碘代喹啉衍生物。
所述步骤A中取代的芳香基叠氮、取代的炔丙醇、碘的物质的量比为1：0.8-1.2：2-6；
所述步骤A中有机溶剂选自甲苯、正己烷、四氢呋喃、二氯甲烷、二氯乙烷，1,2-二氯乙烷中的一种或几种，优选为1,2-二氯乙烷；
所述步骤A中加热回流温度为80-90℃；
所述步骤A中取代的芳香基叠氮为3,4-二甲氧基苯基叠氮；所述取代的炔丙醇为1,1,3-三苯基炔丙醇、1,1-二苯基-3-对甲苯基炔丙醇、1,1-二苯基-3-对甲氧基苯基炔丙醇、1,1-二苯基-3-邻氯苯基炔丙醇、1,1-二苯基-3-间氯苯基炔丙醇、1,1-二苯基-3-对氯苯基炔丙醇、1,1-二苯基-3-对氟苯基炔丙醇、1,1-二苯基-3-丁基炔丙醇、1,1-二(对甲苯基)-3-苯基炔丙醇、1,1-二(对甲氧基苯基)-3-苯基炔丙醇、1,1-二(对氯苯基)-3-苯基炔丙醇、1-苯基-1-对甲氧基苯基-3-苯基炔丙醇、1-(9-芴基)-3-苯基炔丙醇、1-(9-芴基)-3-对甲苯基炔丙醇或1-(9-芴基)-3-对氯苯基炔丙醇；
所述步骤B中分离提纯步骤具体为：以体积比为1:1:1的石油醚、乙酸乙酯、二氯甲烷的混合溶剂为展开剂，将粗产物通过柱层析分离得到产物。
本发明利用取代的芳香基叠氮、取代的炔丙醇与碘串联反应来制备N-芳基-3-碘代喹啉衍生物，具有反应步骤少，产率高的优点。
具体实施方式
下面结合实施例对本发明作详细的说明
实施例1
在两口烧瓶中依次加入3,4-二甲氧基苯基叠氮(0.5mmol)，1,1,3-三苯基炔丙醇(0.5mmol),碘(1.5mmol),ClCH2CH2Cl(3mL)，然后加热至84℃，搅拌15小时(TLC监测)。减压除去溶剂得到粗产品，以石油醚：乙酸乙酯：二氯甲烷＝1:1:1的混合溶剂为展开剂，通过柱层析分离得到棕色固体产物(347mg，产率：75％)。其结构式为：
表征数据为：M.p.229-230℃ 1H NMR(300MHz,CDCl3)δ7.71-7.55(m,7H),7.54-7.38(m,5H),7.37-7.28(m,3H),6.91(s,1H),6.53(s,1H),3.81(s,3H)；3.80(s,3H)；13C NMR(75MHz,CDCl3)δ161.55,157.94,156.37,152.52,140.22,139.29,138.86,137.25,130.95,130.26,130.19,129.97,129.54,129.15,128.53,128.23,127.92,125.83,106.89,100.07,98.49,57.13,56.63；IR(KBr)v 3047,2930,1614,1509,1397,1260,1220,1141,696,566。
实施例2
在两口烧瓶中依次加入3,4-二甲氧基苯基叠氮(0.5mmol)，1,1-二苯基-3-对甲苯基炔丙醇(0.5mmol),碘(1.5mmol),ClCH2CH2Cl(3mL)，然后加热至84℃，搅拌15小时(TLC监测)。减压除去溶剂得到粗产品，以石油醚：乙酸乙酯：二氯甲烷＝1:1:1的混合溶剂为展开剂，通过柱层析分离得到棕色固体产物(357mg，产率：76％)。其结构式为：
表征数据为：M.p.272-273℃；1H NMR(300MHz,DMSO-D6)δ7.65(d,J＝7.7Hz,2H),7.59-7.41(m,7H),7.41-7.22(m,5H),6.94(s,1H),6.43(s,1H),3.73(s,3H),3.65(s,3H),2.47(s,3H)；13C NMR(75MHz,DMSO-D6)δ161.07,157.76,156.82,151.87,140.00,139.89,138.28,137.57,131.17,130.28,129.73,128.62,128.55,128.08,124.67,106.37,100.82,100.06,56.95,56.73,21.65；IR(KBr)v 2930,2850,1618,1506,1404,1263,1224,703cm-1。
实施例3
在两口烧瓶中依次加入3,4-二甲氧基苯基叠氮(0.5mmol)，1,1-二苯基-3-对甲氧基苯基炔丙醇(0.5mmol),碘(1.5mmol),ClCH2CH2Cl(3mL)，然后加热至84℃，搅拌15小时(TLC监测)。减压除去溶剂得到粗产品，以石油醚：乙酸乙酯：二氯甲烷＝1:1:1的混合溶剂为展开剂，通过柱层析分离得到棕色产物(382mg，产率：80％)。其结构式为：
表征数据为：M.p.253-254℃ 1H NMR(300MHz,DMSO-D6)δ7.63(d,J＝6.7Hz,2H),7.56-7.46(m,3H),7.45-7.38(m,4H),7.38-7.23(m,5H),6.98(s,1H),6.41(s,1H),3.89(s,3H),3.76(s,3H),3.65(s,3H)；13C NMR(75MHz,DMSO-D6)δ160.98,160.60,157.83,156.79,151.87,140.06,138.41,138.27,132.47,131.19,130.47,130.31,129.75,128.58,128.11,124.82,115.10,106.50,101.19,100.06,56.93,56.73,55.90；IR(KBr)v 2930,2850,1617,1508,1400,1263,1259,620cm-1。
实施例4
在两口烧瓶中依次加入3,4-二甲氧基苯基叠氮(0.5mmol)，1,1-二苯基-3-邻氯苯基炔丙醇(0.5mmol),碘(1.5mmol),ClCH2CH2Cl(3mL)，然后加热至84℃，搅拌15小时(TLC监测)。减压除去溶剂得到粗产品，以石油醚：乙酸乙酯：二氯甲烷＝1:1:1的混合溶剂为展开剂，通过柱层析分离得到棕色固体产物(288mg，产率：60％)。其结构式为：
表征数据为：M.p.225-226℃ 1H NMR(300MHz,CDCl3)δ7.96-7.86(m,1H),7.85-7.76(m,1H),7.72-7.60(m,4H),7.59-7.52(m,1H),7.52-7.44(m,2H),7.42-7.29(m,4H),7.25-7.14(m,1H),6.78(s,1H),6.56(s,1H),3.85(s,3H),3.81(s,3H).13C NMR(75MHz,CDCl3)δ159.00,158.29,156.56,153.06,139.22,138.94,138.71,136.86,131.60,131.08,130.75,130.66,130.35,130.18,129.90,129.80,128.95,128.90,128.76,128.28,128.22,127.00,125.72,105.90,100.32,98.16,57.19,56.77；IR(KBr)v 2930,1618,1508,1399,1253,1253,1220,618,597cm-1。
实施例5
在两口烧瓶中依次加入3,4-二甲氧基苯基叠氮(0.5mmol)，1,1-二苯基-3-间氯苯基炔丙醇(0.5mmol),碘(1.5mmol),ClCH2CH2Cl(3mL)，然后加热至84℃，搅拌15小时(TLC监测)。减压除去溶剂得到粗产品，以石油醚：乙酸乙酯：二氯甲烷＝1:1:1的混合溶剂为展开剂，通过柱层析分离得到棕色固体产物(350mg，产率：73％)。其结构式为：
表征数据为：M.p.124-125℃；1H NMR(300MHz,DMSO-D6)δ7.85-7.73(m,2H),7.66(d,J＝8.7Hz,1H),7.62-7.48(m,5H),7.48-7.29(m,6H),6.89(s,1H),6.45(s,1H),3.79(s,3H),3.69(s,3H)；13C NMR(75MHz,DMSO-D6)δ159.01,157.98,157.03,152.14,142.26,139.95,138.34,138.08,134.36,131.97,131.30,130.47,130.41,129.72,128.64,128.57,128.08,127.95,127.43,124.51,106.08,100.55,100.12,57.00,56.84；IR(KBr)v 2933,1625,1509,1260,1220,616cm-1。
实施例6
在两口烧瓶中依次加入3,4-二甲氧基苯基叠氮(0.5mmol)，1,1-二苯基-3-对氯苯基炔丙醇(0.5mmol),碘(1.5mmol),ClCH2CH2Cl(3mL)，然后加热至84℃，搅拌15小时(TLC监测)。减压除去溶剂得到粗产品，以石油醚：乙酸乙酯：二氯甲烷＝1:1:1的混合溶剂为展开剂，通过柱层析分离得到棕色固体产物(312mg，产率：65％)。其结构式为：
表征数据为：M.p.263-264℃；1H NMR(300MHz,DMSO-D6)δ7.81(d,J＝8.3Hz,2H),7.62(d,J＝7.4Hz,2H),7.56-7.45(m,5H),7.42(d,J＝7.6Hz,2H),7.39-7.24(m,3H),6.89(s,1H),6.43(s,1H),3.77(s,3H),3.66(s,3H)；13C NMR(75MHz,DMSO-D6)δ159.57,157.87,156.98,152.09,139.97,139.20,138.34,138.14,135.17,131.26,130.75,130.36,130.03,129.72,128.62,128.03,124.58,106.12,100.69,100.14,57.00,56.88；IR(KBr)v 2933,1621,1509,1260,1140,569cm-1。
实施例7
在两口烧瓶中依次加入3,4-二甲氧基苯基叠氮(0.5mmol)，1,1-二苯基-3-对氟苯基炔丙醇(0.5mmol),碘(1.5mmol),ClCH2CH2Cl(3mL)，然后加热至84℃，搅拌15小时(TLC监测)。减压除去溶剂得到粗产品，以石油醚：乙酸乙酯：二氯甲烷＝1:1:1的混合溶剂为展开剂，通过柱层析分离得到棕色固体产物(241mg，产率：51％)。其结构式为：
表征数据为：M.p.231-232℃；1H NMR(300MHz,DMSO-D6)δ7.68-7.59(m,3H),7.59-7.48(m,6H),7.45(dd,J＝8.1,1.6Hz,2H),7.41-7.28(m,3H),6.90(s,1H),6.45(s,1H),3.78(s,3H),3.68(s,3H)；13C NMR(75MHz,DMSO-D6)δ164.77,161.49,159.93,157.88,156.93,152.04,139.99,138.31,138.20,136.78,136.73,131.30,131.24,131.19,130.35,129.72,128.61,128.05,124.78,117.18,116.88,106.21,100.93,100.11,56.98,56.81；IR(KBr)v 2932,1614,1509,1260,1224,844cm-1。
实施例8
在两口烧瓶中依次加入3,4-二甲氧基苯基叠氮(0.5mmol)，1,1-二苯基-3-丁基炔丙醇(0.5mmol),碘(1.5mmol),ClCH2CH2Cl(3mL)，然后加热至84℃，搅拌15小时(TLC监测)。减压除去溶剂得到粗产品，以石油醚：乙酸乙酯：二氯甲烷＝1:1:1的混合溶剂为展开剂，通过柱层析分离得到棕色固体产物(358mg，产率：79％)。其结构式为：
表征数据为：M.p.186-187℃；1H NMR(300MHz,DMSO-D6)δ7.80(s,1H),7.63-7.54(m,2H),7.54-7.44(m,3H),7.43-7.27(m,5H),6.37(s,1H),4.14(s,3H),3.77-3.58(m,5H),1.86-1.60(m,4H),1.08(t,J＝7.1Hz,3H)；13C NMR(75MHz,DMSO-D6)δ162.27,157.54,156.59,152.05,140.16,138.74,137.61,131.10,130.31,130.24,129.75,128.59,128.23,123.62,105.15,100.86,100.27,57.37,56.78,31.26,23.13,14.36；IR(KBr)v 2962,2861,1621,1513,1260,1216,1173,844,692cm-1。
实施例9
在两口烧瓶中依次加入3,4-二甲氧基苯基叠氮(0.5mmol)，1,1-二(对甲苯基)-3-苯基炔丙醇(0.5mmol),碘(1.5mmol),ClCH2CH2Cl(3mL)，然后加热至84℃，搅拌15小时(TLC监测)。减压除去溶剂得到粗产品，以石油醚：乙酸乙酯：二氯甲烷＝1:1:1的混合溶剂为展开剂，通过柱层析分离得到棕色固体产物(391mg，产率：82％)。其结构式为：
表征数据为：M.p.245-246℃；1H NMR(300MHz,DMSO-D6)δ7.80-7.63(m,3H),7.52(d,J＝8.3Hz,2H),7.49-7.42(m,2H),7.39-7.28(m,4H),7.19(d,J＝8.1Hz,2H),6.86(s,1H),6.45(s,1H),3.72(s,3H),3.68(s,3H),2.33(s,3H),2.25(s,3H)；13C NMR(75MHz,DMSO-D6)δ160.72,158.42,156.75,151.85,140.77,140.52,139.83,138.46,137.78,135.66,130.74,130.33,129.77,129.58,129.19,128.57,127.71,124.51,106.25,100.94,100.15,56.96,56.60,21.40,21.34；IR(KBr)v 2939,1618,1516,1260,1137,620cm-1。
实施例10
在两口烧瓶中依次加入3,4-二甲氧基苯基叠氮(0.5mmol)，1,1-二(对甲氧基苯基)-3-苯基炔丙醇(0.5mmol),碘(1.5mmol),ClCH2CH2Cl(3mL)，然后加热至84℃，搅拌15小时(TLC监测)。减压除去溶剂得到粗产品，以石油醚：乙酸乙酯：二氯甲烷＝1:1:1的混合溶剂为展开剂，通过柱层析分离得到棕色固体产物(458mg，产率：93％)。其结构式为：
表征数据为：M.p.253-254℃；1H NMR(300MHz,DMSO-D6)δ7.81-7.64(m,3H),7.57(d,J＝8.9Hz,2H),7.47(d,J＝7.6Hz,2H),7.37(d,J＝8.6Hz,2H),7.08(d,J＝8.9Hz,2H),6.95(d,J＝8.7Hz,2H),6.86(s,1H),6.50(s,1H),3.78(s,3H),3.72(d,J＝6.1Hz,9H)；13CNMR(75MHz,DMSO-D6)δ160.56,160.33,160.16,158.72,156.74,151.81,140.58,138.84,133.06,131.31,130.85,130.31,129.79,129.26,128.57,124.52,115.31,114.01,106.24,101.46,100.19,57.04,56.61,56.11,55.71；IR(KBr)v 2933,2839,1618,1513,1260,1173,1028,833cm-1。
实施例11
在两口烧瓶中依次加入3,4-二甲氧基苯基叠氮(0.5mmol)，1,1-二(对氯苯基)-3-苯基炔丙醇(0.5mmol),碘(1.5mmol),ClCH2CH2Cl(3mL)，然后加热至84℃，搅拌15小时(TLC监测)。减压除去溶剂得到粗产品，以石油醚：乙酸乙酯：二氯甲烷＝1:1:1的混合溶剂为展开剂，通过柱层析分离得到棕色固体产物(229mg，产率：46％)。
其结构式为：
表征数据为：M.p.247-248℃；1H NMR(300MHz,DMSO-D6)δ7.82-7.62(m,7H),7.58-7.43(m,6H),6.90(s,1H),6.49(s,1H),3.77(s,3H),3.75(s,3H)；13C NMR(75MHz,DMSO-D6)δ161.01,157.23,156.78,152.10,140.22,138.66,138.35,137.03,135.94,135.33,131.76,130.71,130.48,129.95,129.86,129.05,128.56,124.70,106.28,100.49,99.96,57.32,56.71；IR(KBr)v 2935,2836,1618,1513,1437,1397,1260,1220,1014,830,703,591cm-1。
实施例12
在两口烧瓶中依次加入3,4-二甲氧基苯基叠氮(0.5mmol)，1-苯基-1-对甲氧基苯基-3-苯基炔丙醇(0.5mmol),碘(1.5mmol),ClCH2CH2Cl(3mL)，然后加热至84℃，搅拌15小时(TLC监测)。减压除去溶剂得到粗产品，以石油醚：乙酸乙酯：二氯甲烷＝1:1:1的混合溶剂为展开剂，通过柱层析分离得到棕色固体产物(382mg，产率：80％)。其结构式为：
表征数据为：M.p.240-241℃；1H NMR(300MHz,DMSO-D6)δ7.83-7.63(m,3H),7.57(d,J＝8.8Hz,2H),7.52-7.28(m,7H),7.05(d,J＝8.8Hz,2H),6.87(s,1H),6.52(s,1H),3.75(s,3H),3.73(s,3H),3.71(s,3H)；13C NMR(75MHz,DMSO-D6)δ160.73,160.39,158.45,156.86,151.90,140.47,138.82,138.48,132.79,130.35,130.27,129.80,129.63,129.36,128.63,128.58,124.64,115.24,106.24,100.40,100.14,57.09,56.64,56.10；IR(KBr)v2939,1643,1506,1401,1253,1220,1112,701cm-1。
实施例13
在两口烧瓶中依次加入3,4-二甲氧基苯基叠氮(0.5mmol)，1-(9-芴基)-3-苯基炔丙醇(0.5mmol),碘(1.5mmol),ClCH2CH2Cl(3mL)，然后加热至84℃，搅拌15小时(TLC监测)。减压除去溶剂得到粗产品，以石油醚：乙酸乙酯：二氯甲烷＝1:1:1的混合溶剂为展开剂，通过柱层析分离得到棕色固体产物(282mg，产率：61％)。其结构式为：
表征数据为：M.p.155-156℃；1H NMR(300MHz,DMSO-D6)δ9.32(d,J＝8.4Hz,1H),8.80(d,J＝7.2Hz,1H),8.74(d,J＝8.1Hz,1H),8.62(d,J＝8.6Hz,1H),8.07(s,1H),8.01(t,J＝7.7Hz,1H),7.88(t,J＝7.6Hz,1H),7.84-7.64(m,4H),7.59(s,2H),7.23(s,1H),6.65(s,1H),3.89(s,3H),3.60(s,3H)；13C NMR(75MHz,DMSO-D6)δ159.12,154.39,151.35,150.59,141.56,135.40,135.06,133.44,130.77,130.56,130.48,130.33,130.22,129.64,128.62,128.27,127.64,125.60,125.44,124.44,123.96,123.81,106.89,105.45,89.10,57.39,56.48；IR(KBr)v 2935,1639,1618,1506,1253,757,616cm-1。
实施例14
在两口烧瓶中依次加入3,4-二甲氧基苯基叠氮(0.5mmol)，1-(9-芴基)-3-对甲苯基炔丙醇(0.5mmol),碘(1.5mmol),ClCH2CH2Cl(3mL)，然后加热至84℃，搅拌15小时(TLC监测)。减压除去溶剂得到粗产品，以石油醚：乙酸乙酯：二氯甲烷＝1:1:1的混合溶剂为展开剂，通过柱层析分离得到棕色固体产物(277mg，产率：59％)。
其结构式为：
表征数据为：M.p.236-237℃；1H NMR(300MHz,DMSO-D6)δ9.39(d,J＝8.1Hz,1H),8.88(d,J＝7.2Hz,1H),8.82(d,J＝8.1Hz,1H),8.69(d,J＝8.4Hz,1H),8.20-8.04(m,2H),8.02-7.81(m,3H),7.75(d,1H),7.65-7.41(m,2H),7.21(s,1H),6.79(s,1H),5.23(s,1H),3.97(s,3H),3.70(s,3H),2.50(s,3H)；13C NMR(75MHz,DMSO-D6)δ159.36,154.36,151.33,150.63,139.87,138.73,135.37,135.05,133.41,130.71,130.61,130.45,130.19,128.64,128.24,127.68,125.56,125.42,124.37,123.93,123.81,107.03,105.39,89.22,57.35,56.54,21.71；IR(KBr)v 2933,1618,1509,1263,1213,1213,761,616cm-1。
实施例15
在两口烧瓶中依次加入3,4-二甲氧基苯基叠氮(0.5mmol)，1-(9-芴基)-3-对氯苯基炔丙醇(0.5mmol),碘(1.5mmol),ClCH2CH2Cl(3mL)，然后加热至84℃，搅拌15小时(TLC监测)。减压除去溶剂得到粗产品，以石油醚：乙酸乙酯：二氯甲烷＝1:1:1的混合溶剂为展开剂，通过柱层析分离得到棕色固体产物(278mg，产率：58％)。其结构式为：
表征数据为：M.p.261-262℃；1H NMR(300MHz,DMSO-D6)δ9.41(d,J＝8.3Hz,1H),8.93(d,J＝7.5Hz,1H),8.87(d,J＝8.1Hz,1H),8.72(d,J＝8.5Hz,1H),8.24-8.07(m,2H),8.08-7.82(m,5H),7.78(d,J＝7.6Hz,1H),7.36(d,J＝7.5Hz,1H),6.78(s,1H),3.99(s,3H),3.77(s,3H)；13C NMR(75MHz,DMSO-D6)δ157.94,154.56,151.60,150.61,140.48,135.57,135.20,135.16,133.56,132.75,130.92,130.78,130.60,130.34,129.92,128.40,127.69,125.70,125.54,124.54,124.07,123.76,106.78,105.63,89.41,57.47,56.76；IR(KBr)v 2935,1618,1513,1477,1260,1166,1014,761,573cm-1。

Claims (7)

1.一种N-芳基-3-碘代喹啉衍生物的制备方法，步骤包括：
A、将取代的芳香基叠氮、取代的炔丙醇与碘在有机溶剂中加热回流，反应12小时以上；
B、减压除去溶剂得到粗产物，将粗产物分离提纯得到产物即N-芳基-3-碘代喹啉衍生物；
所述步骤A中取代的芳香基叠氮为3,4-二甲氧基苯基叠氮；所述取代的炔丙醇为1,1,3-三苯基炔丙醇、1,1-二苯基-3-对甲苯基炔丙醇、1,1-二苯基-3-对甲氧基苯基炔丙醇、1,1-二苯基-3-邻氯苯基炔丙醇、1,1-二苯基-3-间氯苯基炔丙醇、1,1-二苯基-3-对氯苯基炔丙醇、1,1-二苯基-3-对氟苯基炔丙醇、1,1-二苯基-3-丁基炔丙醇、1,1-二(对甲苯基)-3-苯基炔丙醇、1,1-二(对甲氧基苯基)-3-苯基炔丙醇、1,1-二(对氯苯基)-3-苯基炔丙醇、1-苯基-1-对甲氧基苯基-3-苯基炔丙醇、1-(9-芴基)-3-苯基炔丙醇、1-(9-芴基)-3-对甲苯基炔丙醇或1-(9-芴基)-3-对氯苯基炔丙醇；
所述N-芳基-3-碘代喹啉衍生物，其结构式为：
式中，R1～R4为H、C1～C4直链或支链烃基、C1～C4直链或支链烷氧基；R5为苯基或取代苯基、C1～C4直链或支链烃基；R6、R7为苯基或取代苯基；
所述R5、R6、R7为取代苯基时，取代苯基上的取代基为C1～C4直链或支链烃基、C1～C4直链或支链烷氧基或卤素；所述的C1～C4直链烃基为甲基、乙基、丙基或丁基，支链烃基为异丙基、异丁基。
2.如权利要求1所述的制备方法，其特征在于：所述R1、R4为H，R2、R3为甲氧基。
3.如权利要求1所述的制备方法，其特征在于：所述步骤A中取代的芳香基叠氮、取代的炔丙醇、碘的物质的量比为1：0.8-1.2：2-6。
4.如权利要求1所述的制备方法，其特征在于：所述步骤A中有机溶剂选自甲苯、正己烷、四氢呋喃、二氯甲烷、二氯乙烷，1,2-二氯乙烷中的一种或几种。
5.如权利要求4所述的制备方法，其特征在于：所述步骤A中有机溶剂为1,2-二氯乙烷。
6.如权利要求1所述的制备方法，其特征在于：所述步骤A中加热回流温度为80-90℃。
7.如权利要求1所述的制备方法，其特征在于：所述步骤B中分离提纯步骤具体为：以体积比为1:1:1的石油醚、乙酸乙酯、二氯甲烷的混合溶剂为展开剂，将粗产物通过柱层析分离得到产物。
CN201610191732.2A 2016-03-30 2016-03-30 N-芳基-3-碘代喹啉衍生物及其制备方法 Expired - Fee Related CN105622501B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610191732.2A CN105622501B (zh) 2016-03-30 2016-03-30 N-芳基-3-碘代喹啉衍生物及其制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610191732.2A CN105622501B (zh) 2016-03-30 2016-03-30 N-芳基-3-碘代喹啉衍生物及其制备方法

Publications (2)

Publication Number Publication Date
CN105622501A CN105622501A (zh) 2016-06-01
CN105622501B true CN105622501B (zh) 2019-02-19

Family

ID=56037886

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610191732.2A Expired - Fee Related CN105622501B (zh) 2016-03-30 2016-03-30 N-芳基-3-碘代喹啉衍生物及其制备方法

Country Status (1)

Country Link
CN (1) CN105622501B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109096185A (zh) * 2018-09-18 2018-12-28 江西科技师范大学 一种4-溴-喹啉衍生物的合成方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2603345C (en) * 2005-04-01 2017-05-02 Insa Rouen New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Selective endo and exo Iodocyclizations in the Synthesis of Quinolines and Indoles;Karl O. Hessian，et al.;《ORGANIC LETTERS》;20061231;第8卷(第2期);第243-246页
Synthesis of Substituted Quinolines by the Electrophilic Cyclization of N-(2-Alkynyl)anilines;Xiaoxia Zhang，et al.;《Tetrahedron》;20101231;第66卷(第6期);第1177页

Also Published As

Publication number Publication date
CN105622501A (zh) 2016-06-01

Similar Documents

Publication Publication Date Title
Lukin et al. New practical synthesis of indazoles via condensation of O-fluorobenzaldehydes and their O-methyloximes with hydrazine
Kamal et al. One-pot, three-component approach to the synthesis of 3, 4, 5-trisubstituted pyrazoles
Singh et al. DABCO-Promoted three-component regioselective synthesis of functionalized chromen-5-ones and pyrano [3, 2-c] chromen-5-ones via direct annulation of α-oxoketene-N, S-arylaminoacetals under solvent-free conditions
JP2002516909A (ja) 置換１−（４−アミノフェニル）ピラゾール及び抗炎症剤としてのそれらの使用
Jin et al. 4-([1, 2, 4] Triazolo [1, 5-a] pyridin-6-yl)-5 (3)-(6-methylpyridin-2-yl) imidazole and-pyrazole derivatives as potent and selective inhibitors of transforming growth factor-β type I receptor kinase
Gudipudi et al. Rational design and synthesis of novel 2-(substituted-2 H-chromen-3-yl)-5-aryl-1 H-imidazole derivatives as an anti-angiogenesis and anti-cancer agent
Sravanthi et al. Synthesis, docking, and evaluation of novel thiazoles for potent antidiabetic activity
Jin et al. Synthesis and biological evaluation of 1-substituted-3 (5)-(6-methylpyridin-2-yl)-4-(quinolin-6-yl) pyrazoles as transforming growth factor-β type 1 receptor kinase inhibitors
Dai et al. Substituent-oriented synthesis of substituted pyrazoles/chromeno [3, 2-c] pyrazoles via sequential reactions of chromones/3-chlorochromones and tosylhydrazones
Abbiati et al. A valuable heterocyclic ring transformation: from isoxazolin-5 (2H)-ones to quinolines
Wu et al. Discovery of 2-[5-(4-Chloro-phenyl)-1-(2, 4-dichloro-phenyl)-4-ethyl-1 H-pyrazol-3-yl]-1, 5, 5-trimethyl-1, 5-dihydro-imidazol-4-thione (BPR-890) via an Active Metabolite. A Novel, Potent and Selective Cannabinoid-1 Receptor Inverse Agonist with High Antiobesity Efficacy in DIO Mice
Rajeev et al. Base-Induced Cyclization of active methylene isocyanides with xanthate esters: an efficient method for the synthesis of 5-Alkoxy-4-(tosyl/ethoxycarbonyl)-1, 3-thiazoles
Chalyk et al. Regioselective synthesis of functionalized 3-or 5-fluoroalkyl isoxazoles and pyrazoles from fluoroalkyl ynones and binucleophiles
CN110204487B (zh) 一种喹啉衍生物的合成方法
Elkady et al. Novel promising benzoxazole/benzothiazole‐derived immunomodulatory agents: Design, synthesis, anticancer evaluation, and in silico ADMET analysis
Li et al. Design, synthesis and biological evaluation of 2, 4-disubstituted oxazole derivatives as potential PDE4 inhibitors
Ren et al. Copper-catalyzed aerobic oxidative cyclization of ketoxime acetates with pyridines for the synthesis of imidazo [1, 2-a] pyridines
CN105622501B (zh) N-芳基-3-碘代喹啉衍生物及其制备方法
Zhai et al. Effective laboratory-scale preparation of axitinib by Two CuI-catalyzed coupling reactions
Goncalves et al. Synthesis of a new polyfunctionalised pyrimidine-4-carboxylate and its application for the construction of a series of pyrimidine derivatives
El-Sayed et al. An efficient and facile multicomponent synthesis of 4, 6-diarylpyridine derivatives under solvent-free conditions
Wang et al. A one-pot approach to 4, 5-dihydropyrazoles from ketones, arylacetylenes, and hydrazines
Laufer et al. Isoxazolone based inhibitors of p38 MAP kinases
Wu et al. Synthesis and fungicidal activity of novel imidazo [4, 5-b] pyridine derivatives
Dadashpour et al. Synthesis and anticancer activity of benzimidazole/benzoxazole substituted triazolotriazines in hepatocellular carcinoma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190219